Brain tumors present a particular challenge as the risk of harming healthy brain tissue can severely limit doctors' ability to use surgery, radiation or other treatments. Still, researchers are making steady progress to extend survival and improve patients' quality of life. For example, recent genetic discoveries have led to the identification of distinct sub-types of brain tumors, allowing doctors to personalize care to individual patients and providing potential targets for new treatments.
A federally-funded clinical trial shows that adding a chemotherapy regimen called PCV (procarbazine, CCNU, and vincristine) to radiation therapy slows cancer growth of grade 2 glioma and extends survival by a median of 5 years. Grade 2 gliomas are a rare, slow-growing type of brain tumor that occur most often in young people. As a result of this study, PCV chemotherapy after radiation therapy is now the standard of care for high-risk, low-grade gliomas.